5. Xu Jing,Gao Yi,Luan Xiaotian et al. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.[J] .Cancer Chemother Pharmacol, 2022, 89: 683-695. 6. Yap Timothy A,Kristeleit Rebecca,Mic...
Here, we evaluated the combination of olaparib or veliparib with therapeutically relevant DNA-targeted drugs, including the topoisomerase I inhibitor camptothecin, the alkylating agent temozolomide, the cross-linking agent cisplatin, and the topoisomerase II inhibitor etoposide at the cellular and molecular...
5. Xu Jing,Gao Yi,Luan Xiaotian et al. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.[J] .Cancer Chemother Pharmacol, 2022, 89: 683-695. 6. Yap Timothy A,Kristeleit Rebecca,Michalarea Vasiliki et al. BRCA1/2Phase I Trial of the PARP Inhibitor...
The controversy over the optimal chemotherapy-PARP inhibitor combination and sequencing continues [54]. Notably, the GeparOcto trial found no significant difference in pathological complete response (pCR) rates between two intensive chemotherapy regimens, regardless of the addition of carboplatin [55]. S...
PARP inhibitors: A new era of targeted therapy evidence and clinical applications of PARP inhibitors especially in nonBRCA cancers, and review the combination strategies compatible with PARP inhibitor therapy... S Tangutoori,P Baldwin,S Sridhar - 《Maturitas》 被引量: 84发表: 2015年 ...
Plan PARP inhibitor–based combination therapy for patients with advanced prostate cancer, considering HRRm and BRCAm status, recent guideline updates, FDA approvals, and expert recommendations Identify patients with prostate cancer eligible for enrollment on clinical trials investigating PARP inhibitor-based...
[30]Pujade-Lauraine E, Selle F, Scambia G, et al. LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): phase Ⅲb OReO/ENGOT Ov-38 trial[...
Multidrug resistance protein oHSVs: Oncolytic herpes simplex viruses GSCs: Glioblastoma stem cells IR: Ionizing radiation WBRT: Whole brain radiation therapy HDACi: Histone deacetylation inhibitors DNMTi: DNA methyltransferase inhibitor PFS: Progression-free survival...
Thus, combination with PARP1 inhibitor exhibited marked synergistic anticancer effect in both in vitro studies and in vivo experiments using a GC PDx model. Especially, Chk1 inhibitor combined with PARPis may be a more effective therapeutic strategy in GC. PARP inhibitor olaparib combined with WEE...
(a PARP1 inhibitor) has demonstrated safety and activity in a preliminary analysis of 40 patients, including those with BRCA mutated TNBC, with an ORR of 25% and a disease control rate of 53%. This agent is being investigated for its efficacy either as monotherapy or in combination with ...